Clinic
Oakland Physicians Medical Center, LLC
Oakland Physicians Medical Center, LLC was paid $4.62M by Medicaid between Jan 2018 and Dec 2024, across 135 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 34% of everything it billed.
33Billing provider infoOAKLAND PHYSICIANS MEDICAL CENTER, LLC
PONTIAC, MI 48341
PONTIAC, MI 48341
33aNPI1619125788assigned 09/03/2008
33bProvider typeRadiology Clinic/Center
28Total paid$4.62M
24GClaims194,930
24DCodes billed135
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Radiology Clinic/Center providers in Michigan
Rank by total paid#1 of 7
Median peer was paid$31K
This provider vs. median151×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,547 | $784K | |
| 2019 | 12,542 | $546K | |
| 2020 | 10,348 | $366K | |
| 2021 | 12,862 | $489K | |
| 2022 | 8,012 | $305K | |
| 2023 | 25 | $50K | |
| 2024incomplete | 141,594 | $2.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 34% | 12,612 | 11,074 | $1.59M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 5.7% | 2,900 | 2,762 | $264K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 5.3% | 92 | 89 | $244K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 5.0% | 203 | 201 | $229K |
| 80061 | Lipid panel | 3.4% | 7,452 | 7,169 | $159K |
| 87634 | 2.6% | 2,688 | 2,555 | $121K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.6% | 3,078 | 2,758 | $119K |
| 87529 | 2.5% | 2,768 | 2,610 | $113K | |
| G0378 | Hospital observation service, per hour | 2.3% | 1,050 | 918 | $105K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.2% | 5,015 | 4,777 | $101K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.2% | 5,806 | 5,626 | $100K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.1% | 1,824 | 1,766 | $99K |
123 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.1% | 4,847 | $97K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 1,465 | $89K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.9% | 4,118 | $88K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.8% | 3,103 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.7% | 7,428 | $79K |
| 87481 | 1.6% | 2,899 | $75K | |
| 87511 | 1.2% | 2,623 | $54K | |
| 80053 | Comprehensive metabolic panel | 1.2% | 11,996 | $54K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,608 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.0% | 7,732 | $48K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,161 | $46K |
| 82607 | <1% | 5,071 | $46K | |
| 87563 | <1% | 2,280 | $45K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,337 | $39K |
| 84439 | <1% | 4,866 | $29K | |
| 82728 | <1% | 2,480 | $23K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,481 | $22K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 251 | $21K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 622 | $16K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 650 | $16K |
| 84480 | <1% | 1,510 | $15K | |
| 82746 | <1% | 1,556 | $15K | |
| 86803 | <1% | 1,579 | $14K | |
| 80074 | <1% | 488 | $14K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 868 | $13K |
| 83550 | <1% | 2,237 | $13K | |
| 83735 | <1% | 2,946 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,591 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 372 | $12K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 224 | $12K |
| 83540 | <1% | 2,617 | $11K | |
| 84481 | <1% | 1,060 | $11K | |
| 84153 | <1% | 919 | $11K | |
| 84403 | <1% | 505 | $9K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 131 | $9K |
| 87186 | <1% | 829 | $9K | |
| 82043 | <1% | 1,997 | $8K | |
| 84100 | <1% | 2,240 | $7K | |
| 82670 | <1% | 372 | $7K | |
| 82570 | <1% | 1,966 | $7K | |
| 84702 | <1% | 648 | $6K | |
| 84146 | <1% | 436 | $6K | |
| 83001 | <1% | 443 | $6K | |
| 84550 | <1% | 1,832 | $6K | |
| 86696 | <1% | 468 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,204 | $5K |
| 86592 | <1% | 1,387 | $5K | |
| 87077 | <1% | 965 | $5K | |
| 83002 | <1% | 406 | $5K | |
| 87340 | <1% | 832 | $5K | |
| 87088 | <1% | 1,107 | $5K | |
| 87070 | <1% | 1,276 | $4K | |
| 86304 | <1% | 258 | $4K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 100 | $4K |
| 86301 | <1% | 242 | $4K | |
| 86695 | <1% | 465 | $4K | |
| 85651 | <1% | 1,316 | $4K | |
| 86317 | <1% | 357 | $3K | |
| 86141 | <1% | 362 | $3K | |
| 81001 | <1% | 3,488 | $3K | |
| 86704 | <1% | 358 | $3K | |
| 86431 | <1% | 673 | $3K | |
| 86708 | <1% | 319 | $3K | |
| 93970 | <1% | 30 | $2K | |
| 82550 | <1% | 453 | $2K | |
| 83880 | <1% | 1,060 | $2K | |
| 86480 | <1% | 47 | $2K | |
| 85027 | <1% | 429 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $2K |
| 86769 | <1% | 150 | $2K | |
| 83690 | <1% | 858 | $2K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 33 | $1K |
| 82150 | <1% | 934 | $1K | |
| 86038 | <1% | 168 | $1K | |
| 86140 | <1% | 341 | $1K | |
| 86632 | <1% | 149 | $1K | |
| 82040 | <1% | 261 | $862.63 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,042 | $779.68 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,658 | $733.68 |
| 84460 | <1% | 220 | $731.66 | |
| 80076 | <1% | 172 | $730.69 | |
| 84450 | <1% | 210 | $690.59 | |
| 83013 | <1% | 13 | $626.13 | |
| 80305 | <1% | 2,510 | $547.47 | |
| 82378 | <1% | 40 | $518.01 | |
| 85610 | <1% | 171 | $436.70 | |
| 81003 | <1% | 297 | $430.81 | |
| 87653 | <1% | 15 | $391.28 | |
| 87640 | <1% | 15 | $391.28 | |
| 82553 | <1% | 39 | $326.89 | |
| 80051 | <1% | 81 | $314.10 | |
| 83970 | <1% | 13 | $301.64 | |
| 73630 | <1% | 26 | $284.58 | |
| 71045 | Radiologic examination, chest; single view | <1% | 19 | $284.58 |
| 85730 | <1% | 67 | $277.51 | |
| 81025 | <1% | 2,134 | $273.10 | |
| 82248 | <1% | 65 | $190.78 | |
| 86703 | <1% | 83 | $173.64 | |
| 86762 | <1% | 23 | $173.37 | |
| 84484 | <1% | 1,910 | $172.54 | |
| 88174 | <1% | 17 | $150.11 | |
| 83615 | <1% | 45 | $147.14 | |
| 81000 | <1% | 1,217 | $141.42 | |
| 82465 | <1% | 51 | $137.76 | |
| 87400 | <1% | 902 | $136.17 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $112.16 |
| 82947 | <1% | 46 | $110.89 | |
| 84436 | <1% | 38 | $90.48 | |
| 87430 | <1% | 358 | $79.58 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 45 | $77.10 |
| 82977 | <1% | 17 | $72.18 | |
| 84520 | <1% | 30 | $69.07 | |
| 82565 | <1% | 15 | $42.89 | |
| 83605 | <1% | 786 | $27.99 | |
| 87040 | <1% | 15 | $21.10 | |
| 82948 | <1% | 252 | $16.72 | |
| 94760 | <1% | 1,078 | $12.50 | |
| 86706 | <1% | 14 | $7.08 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 56 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 220 | $0.00 |
| 96376 | 0% | 472 | $0.00 | |
| 85379 | 0% | 13 | $0.00 | |
| 87480 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialARORA, LALIT (COO)
| Provider | Location | Paid |
|---|---|---|
| PGH Medical Group PC | Pontiac, MI | $1.69M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.